• June 2021
    CATUG Biotechnology was incorporated in Suzhou BioBAY
  • August 2021
    Wuhan CATUG, a wholly-owned subsidiary, was incorporated in Biolake
  • September 2021
    The R&D centers in both Suzhou and Wuhan were put into operation, and the first strategic cooperation agreement was signed.
  • November 2021
    An angel round of financing of over 10 million US dollars was completed
  • December 2021
    The Wuhan Plasmid GMP plant was put into operation, with the order amount surpassed RMB 50 million in the year
  • January 2022

    Suzhou GMP commercial base site, which is in line with international standards, was initiated for construction

  • March 2021
    Series A financing of over 10 million US dollars was completed 
  • April 2022

    The new office in Suzhou was put into use, with more than 100 employees employed

  • August 2022

    Gusu entrepreneurship leader

    Most Growing CXO Enterprise TOP10 in China's Biomedical Industry Value List

  • Septemper 2022
    Awarded the title of Major Entrepreneurial Leader in SIP
    The BioCon Awards' CDMO of the Year
  • October 2022
    The first mRNA CDMO GMP base was officially completed
  • December 2022

    CATUG U.S. Company Established

  • March 2023
    Delivery of the First Overseas Order
  • June 2023
    Publication of Full-Process GMP Data for mRNA
  • January 2024
    Delivery of mRNA Multivalent Vaccine Plasmid Project (Phase 1)
  • May 2024
    CATUG Switzerland Company Established
  • June 2024
    Series A+ Financing Completed
  • May 2025
    Landing of the First Overseas MNC Million-Dollar Order
  • June 2025
    EU QP Audit Passed, Compliance Report Received

  • June 2021
  • August 2021
  • September 2021
  • November 2021
  • December 2021
  • January 2022
  • March 2021
  • April 2022
  • August 2022
  • Septemper 2022
  • October 2022
  • December 2022
  • March 2023
  • June 2023
  • January 2024
  • May 2024
  • June 2024
  • May 2025
  • June 2025